Literature DB >> 16219398

Immune responses to human papillomavirus.

Margaret Stanley1.   

Abstract

The immune system uses innate and adaptive immunity to recognize and combat foreign agents that invade the body, but these methods are sometimes ineffective against human papillomavirus (HPV). HPV has several mechanisms for avoiding the immune system. HPV infects, and multiplies in keratinocytes, which are distant from immune centers and have a naturally short lifespan. The naturally short life cycle of the keratinocyte circumvents the need for the virus to destroy the cell, which would trigger inflammation and immune response. In addition, HPV downregulates the expression of interferon genes. Despite viral immune evasion, the immune system effectively repels most HPV infections, and is associated with strong localized cell mediated immune responses. New prophylactic L1 virus-like protein vaccines for HPV 16 and 18 and HPV 6, 11, 16, and 18 are in phase 3 trials. Available data suggests that these vaccines are safe, produce high levels of antibodies, and are effective at preventing HPV infection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16219398     DOI: 10.1016/j.vaccine.2005.09.002

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  150 in total

1.  Progression and regression of premalignant cervical lesions in HIV-infected women from Soweto: a prospective cohort.

Authors:  Tanvier Omar; Sheree Schwartz; Colleen Hanrahan; Tebogo Modisenyane; Nkeko Tshabangu; Jonathan E Golub; James A McIntyre; Glenda E Gray; Lerato Mohapi; Neil A Martinson
Journal:  AIDS       Date:  2011-01-02       Impact factor: 4.177

2.  Review of Gardasil.

Authors:  Diane M Harper; Stephen L Vierthaler; Jennifer A Santee
Journal:  J Vaccines Vaccin       Date:  2010-11-23

Review 3.  Vaccinations for Anal Squamous Cancer: Current and Emerging Therapies.

Authors:  John Berry; Sean C Glasgow
Journal:  Clin Colon Rectal Surg       Date:  2018-11-02

Review 4.  Human papillomavirus testing in the prevention of cervical cancer.

Authors:  Mark Schiffman; Nicolas Wentzensen; Sholom Wacholder; Walter Kinney; Julia C Gage; Philip E Castle
Journal:  J Natl Cancer Inst       Date:  2011-01-31       Impact factor: 13.506

5.  The human papillomavirus vaccine: The promise of cervical cancer prevention.

Authors:  Bl Johnston; Jm Conly
Journal:  Can J Infect Dis Med Microbiol       Date:  2007-07       Impact factor: 2.471

6.  Differential in vitro immortalization capacity of eleven (probable) [corrected] high-risk human papillomavirus types.

Authors:  Denise M Schütze; Peter J F Snijders; Leontien Bosch; Duco Kramer; Chris J L M Meijer; Renske D M Steenbergen
Journal:  J Virol       Date:  2013-11-20       Impact factor: 5.103

7.  Association between toll-like receptor expression and human papillomavirus type 16 persistence.

Authors:  Ibrahim I Daud; Mark E Scott; Yifei Ma; Stephen Shiboski; Sepideh Farhat; Anna-Barbara Moscicki
Journal:  Int J Cancer       Date:  2011-02-15       Impact factor: 7.396

Review 8.  Molecular mechanisms of human papillomavirus-related carcinogenesis in head and neck cancer.

Authors:  Farhoud Faraji; Munfarid Zaidi; Carole Fakhry; Daria A Gaykalova
Journal:  Microbes Infect       Date:  2017-06-12       Impact factor: 2.700

Review 9.  Immune therapy for human papillomaviruses-related cancers.

Authors:  Ricardo Rosales; Carlos Rosales
Journal:  World J Clin Oncol       Date:  2014-12-10

10.  Immunosuppressive cytokine Interleukin-10 (IL-10) is up-regulated in high-grade CIN but not associated with high-risk human papillomavirus (HPV) at baseline, outcomes of HR-HPV infections or incident CIN in the LAMS cohort.

Authors:  Stina Syrjänen; Paulo Naud; Luis Sarian; Sophie Derchain; Cecilia Roteli-Martins; Adhemar Longatto-Filho; Silvio Tatti; Margherita Branca; Mojca Erzen; L S Hammes; S Costa; Kari Syrjänen
Journal:  Virchows Arch       Date:  2009-11-12       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.